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Background: Cognitive impairment, including dementia, is a major health concern with the increasing aging
population. Preventive measures to delay cognitive decline are of utmost importance. Alzheimer’s disease (AD) is
the most frequent cause of dementia, increasing in prevalence from <1% below the age of 60 years to >40%
above 85 years of age.
Methods: We systematically reviewed selected modifiable factors such as education, smoking, alcohol, physical
activity, caffeine, antioxidants, homocysteine (Hcy), n-3 fatty acids that were studied in relation to various cognitive
health outcomes, including incident AD. We searched MEDLINE for published literature (January 1990 through
October 2012), including cross-sectional and cohort studies (sample sizes > 300). Analyses compared study finding
consistency across factors, study designs and study-level characteristics. Selecting studies of incident AD, our
meta-analysis estimated pooled risk ratios (RR), population attributable risk percent (PAR%) and assessed publication bias.
Results: In total, 247 studies were retrieved for systematic review. Consistency analysis for each risk factor suggested
positive findings ranging from ~38.9% for caffeine to ~89% for physical activity. Education also had a significantly higher
propensity for “a positive finding” compared to caffeine, smoking and antioxidant-related studies. Meta-analysis of 31
studies with incident AD yielded pooled RR for low education (RR = 1.99; 95% CI: 1.30-3.04), high Hcy (RR = 1.93; 95% CI:
1.50-2.49), and current/ever smoking status (RR = 1.37; 95% CI: 1.23-1.52) while indicating protective effects of higher
physical activity and n-3 fatty acids. Estimated PAR% were particularly high for physical activity (PAR% = 31.9; 95% CI:
22.7-41.2) and smoking (PAR%=31.09%; 95% CI: 17.9-44.3). Overall, no significant publication bias was found.
Conclusions: Higher Hcy levels, lower educational attainment, and decreased physical activity were particularly strong
predictors of incident AD. Further studies are needed to support other potential modifiable protective factors, such
as caffeine.
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Cognitive function refers to those mental processes that
are crucial for the conduct of the activities of daily living.
Such mental processes include attention, short-term and
long-term memory, reasoning, coordination of movement
and planning of tasks [1]. The prevalence of brain dis-
orders affecting cognition (such as stroke and dementia)
increases steadily in a linear fashion with age [2]. Cognitive* Correspondence: baydounm@mail.nih.gov
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unless otherwise stated.impairment is a major health concern affecting loss of
independence in daily activities in old age. Thus, special
attention should be devoted to its prevention [3].
Dementia is relatively frequent in the elderly population
and was shown to affect about 6.4% of European subjects
over the age of 65 years [4]. A review of 50 original articles
published between 1989 and 2002 using international data
showed that prevalence of dementia for the very old group
(85 years and over) varied from 16.7% in China [5] to 43%
in Germany [6]. This variability was also reflected within
separate age groups among the very old, ranging from
9.6% to 32% for the 85–89 age category and from 41% toal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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http://www.biomedcentral.com/1471-2458/14/64358% for the 95+ age group. Incidence varied between 47
and 116.6 per 1000 and a separate meta-analytic study
estimated the incidence in that age group (i.e. 85+) to
be around 104 per 1000 [7,8].
Alzheimer’s disease (AD) is the most frequent cause of
dementia, increasing in prevalence from less than 1%
below the age of 60 years to more than 40% above
85 years of age. The initial phase is generally marked by
a progressive deterioration of episodic memory. Other
impairments may be entirely absent in the beginning or
consist of mild disturbances in naming and executive
function. When the process advances, impairment spreads
to other aspects of memory and other domains of cogni-
tion. Despite lack of curative treatment, epidemiological
evidence reveals important risk factors for sporadic AD,
many of which are non-modifiable (e.g. ApoE ε4, age and
sex). This highlights the importance for further evaluation
of modifiable risk and preventive factors in that these po-
tential factors may not only delay the onset of cognitive
decline, but also can be easily treated. Aside from AD, less
frequently occurring forms of dementia include vascular
dementia (VaD), mixed dementia, dementia with Lewy
bodies (DLB) and Parkinson’s disease with dementia
(PD-D), diagnostic criteria for which are described in
Table 1. The relative prevalence of AD and VaD and
the mixed version of both remain debatable. Ott and
colleagues [9] estimated that for the very old, the
prevalence of AD was 26.8% while that of VaD was 4.4%.
However, VaD appears to be more frequent than AD in
certain Japanese and Chinese populations [10].
The present review focuses on selected modifiable risk
and protective factors of cognitive impairment, cognitive
decline and dementia (including AD), given that they are
commonly studied and provide reliable and comparable
data. In particular, we focused on the risk and protective
factors that could be grouped under three broad categories,
namely socioeconomic, behavioral, and nutritional. Conse-
quently, other known risk factors that are modifiable but
did not fall under these categories were excluded (e.g.
obesity, type 2 diabetes, hypertension, depression, trau-
matic head injury etc.). In addition, the latter risk factors
are potential mediating factors in the causal pathway
between our selected factors and cognitive outcomes
(e.g. obesity, depression, type 2 diabetes and hypertension
may be on the causal pathway between physical activity
and cognition; the same for diet→depression, obesity, type
2 diabetes, hypertension→cognition) and thus are more
appropriately studied together rather than with their ante-
cedent putative causes. This is the first study to systemat-
ically review those selected modifiable risk and protective
factors for cognitive health outcomes in cross-sectional
and cohort studies while comparing the consistency of
association between those factors and across study-level
characteristics. It is also among few recent studies tocompare the strength of association across those fac-
tors in relation to incident AD using a similar approach




Using MEDLINE, we conducted a systematic review of
the literature on cognitive function, decline and dementia
focusing on specific risk factors. We considered both
original research published between January 1990 and
October 2012. We did not include titles prior to 1990 to
ensure that diagnostic criteria for dementia and AD
were comparable across studies. After an initial search
using MESH keywords for risk factors (i.e. education,
smoking, physical activity, caffeine/coffee/tea, alcohol,
antioxidant/vitamin E, homocysteine and fatty acid) and
a title containing the words (cognitive, dementia and
Alzheimer), we assessed the retrieved papers for relevance
by reading the titles and abstracts. Among those that were
selected for review, information was retrieved including
study design, contextual setting, sample size, main outcome
and key findings.
Final inclusion criteria were: (1) Study sample size > 300.
Although this number is arbitrary, it was based on the fact
that some study outcomes were relatively rare (e.g. incident
AD: <10%) and thus a smaller sample size for a cohort
study for example might yield an underpowered study,
depending on the distribution of the risk factor. (2)
Study design is either cross-sectional or cohort study
(thus case-control studies, review articles, commentaries,
and basic science papers were excluded); (3) Outcomes in-
clude dementia, AD, cognitive function, cognitive decline
or cognitive impairment (including MCI)). Although all
types of dementia were presented in our description of se-
lected studies, focus was on the more prevalent sub-types
including AD and VaD (4) Baseline sample includes
general healthy population rather than special groups at
risk (e.g. coronary heart disease patients). For the “cognitive
decline” and “cognitive function” outcomes, we searched
risk factors in the title to expand the range of studies
selected beyond those based just on MESH keywords
(i.e. “caffeine,” “alcohol” and all other risk factors were
also searched in titles when the outcome was “cognitive”).
Both cohort and cross-sectional studies that were selected
are presented in Table 2. The MEDLINE search and the
studies excluded are laid out in Figure 1, showing main
reasons for exclusion and final number of studies included
for each risk factor. After inclusion of a study, we did not
examine cross-references in order to ensure the compar-
ability of the search strategy between risk factors.
Out of a total search of 6,837 titles and abstracts
between 1990 and 2012 (range:126 for caffeine to 1,692 for
education), 247 published original epidemiologic studies
Table 1 Diagnostic criteria of Alzheimer’s Disease (AD),






Development of multiple cognitive
deficits, with both memory impairment
and one (or more) of the following
cognitive disturbances:
Aphasia (language disturbance)
Apraxia (learned motor skills disturbance)
Agnosia (visuospatial/sensory disturbance)
Executive functioning (foresight, planning,
insight anticipation)
Significant impairment in social or
occupational functioning, representing
a significant decline from a previous
level of functioning
Other diagnostic criteria: Hachinski




Cognitive decline from previous higher
level of function in three areas of function
including memory.
Evidence of cerebrovascular disease by
examination
Evidence of cerebrovascular disease by
neuroimaging
Onset either abrupt or within three
months of a recognized stroke.
Vascular Dementia (VaD)
(Modified Hachinski Ischemia










Other diagnostic criteria: ICD-10;
DSM-IV
Mixed Dementias (MDs)
Hachinski Ischemic score Score based on clinical features:
≤4 = AD; ≥7 = VaD; intermediate
score of 5 or 6 = MD.
ICD-10 Cases that met criteria for VaD and AD
DSM-IV Cases with criteria for primary
degenerative dementia of the Alzheimer
type and clinical or neuroimagery
feature of VaD.
ADDTC Presence of ischemic vascular disease
and a second systemic or brain disorder.
NINDS-AIREN Typical AD associated with clinical
and radiological evidence of stroke.
Table 1 Diagnostic criteria of Alzheimer’s Disease (AD),





Behavioral or cognitive deficits
manifested by either (1) or (2):
(1) Early and progressive personality
change, with problems in modulating
behavior; inappropriate responses/
activities.
(2) Early and progressive language
changes, with problems in language
expression, word meaning, severe
dysnomia.
Deficits represent a decline from
baseline and cause significant
impairment in social and occupational
functioning.
Course characterized by gradual onset
and continuing decline in function.
Other causes (eg, stroke, delirium) are
excluded








Fluctuating in cognitive performance:
Marked variation in cognition or function,
or episodic confusion/decreased
responsiveness.
Visual hallucinations: Usually well formed,
unprovoked, benign.
Parkinsonism: Can be identical to










Abbreviations: ADDTC: Alzheimer's Disease Diagnostic and Treatment
Centers; DSM-IV: Diagnostic and Statistical Manual, 4th edition; ICD-10:
International Classification of Disease, 10th edition; NINCDS-ADRDA: National
Institute of Neurological and Communicative Disorders and Stroke – the
Alzheimer's Disease and Related Disorders Association; NINDS-AIREN: National
Institute of Neurological and Communicative Disorders and Stroke–Association
Internationale pour la Recherche et l’Enseignement en Neurosciences; PD-D:
Parkinson’s disease with dementia.
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our review. A database was built accordingly using Endnote
ver. X3 [259]. Each study was summarized in Table 2 by
listing the sample characteristics (age, gender, country),
study design, sample size and type of outcome. Given the
diversity of types of outcomes, a quantitative meta-analysis
for all studies with all outcomes was not possible. Thus,
a qualitative method to assess overall consistency was
Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review
Study Age/gender Year Country Study design Sample size Outcomes Findings
(1) Education Hypothesis: Lower education is associated with lower cognitive function or higher rate of cognitive decline or increased risk of dementia(including AD)
[21] 65+/B 1990 China Cross-sectional N = 5,055 Prevalent AD and dementia +
[22] Mean:58.5/B 1991 Nigeria Cross-sectional N = 1,350 Cognitive function +
[23] 65+/B 1992 France Cross-sectional N = 2,792 Cognitive function +
[24] 68-77/B 1992 Finland Cross-sectional N = 403 Cognitive function +
[25] 65+/B 1993 US Cohort N = 4,485 Cognitive decline +
[26] 75+/B 1994 England Cohort N = 1,195 Indicent dementia 0
[27] 65+/B 1994 US Cohort N = 10,294 Incident cognitive impairment +
[28] 55+/B 1995 US Cohort N = 3,330 Incident AD and VaD +(VaD)
[29] 18+/B 1995 US Cohort N = 14,883 Indicent dementia +
[9] 55-106/B 1995 The Netherlands Cross-sectional N = 7,528 Prevalent dementia, AD and VaD +
[30] 65+/B 1996 US Cross-sectional N = 2,212 Prevalent dementia and cognitive
impairment
+
[31] 68-78/B 1996 Finland Cross-sectional N = 403 Cognitive decline +
[32] 70+/B 1997 Australia Cohort N = 652 Cognitive decline +
[33] 65+/B 1997 US Cohort N = 642 Incident AD +
[34] 50-80/B 1997 Austria Cross-sectional N = 1,927 Cognitive function +
[35] Mean:75/M 1997 The Netherlands Cohort N = 528 Cognitive decline +
[36] 69-74/M 1997 Sweden Cross-sectional N = 504 Cognitive function +
[37] 55-84/B 1997 The Netherlands Cohort N = 5,825 Cognitive function, decline and
incident/prevalent dementia
+
[38] 65-84/B 1997 The Netherlands Cohort N = 2,063 Incident dementia +(IQ better predcitor)
[39] 47-68/B 1998 US Cross-sectional N = 14,000 Cognitive function +
[40] 60+/B 1998 Italy Cross-sectional N = 495 Prevalent dementia 0
[41] 65+/B 1998 Taiwan Cross-sectional N = 2,915 Prevalent dementia, AD and VaD +(AD)
[42] 18+/B 1999 US Cohort N = 1,488 Cognitive decline +
[43] 65+/B 1999 France Cohort N = 3,675 Incident AD +
[44] 55-106/B 1999 The Netherlands Cohort N = 6,827 Incident dementia +(women)
[45] 85+/B 2000 Sweden Cohort N = 494 Cognitive decline and function +
[46] 75+/B 2001 Sweden Cohort N = 1,296 Incident dementia and AD +
[47] 65+/B 2002 Spain Cohort N = 557 Cognitive decline +
[48] 70+/B 2002 US Cross-sectional N = 6,577 Cognitive function +



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[50] 65+/B 2002 Italy Cross-sectional N = 1,016 Prevalent AD and VaD +
[51] 45-59/M 2002 US Cross-sectional N = 1,839 Cognitive function +
[52] 70-79/W 2003 US Cohort N = 19,319 Cognitive function and decline +
[53] 70-79/B 2005 US Cohort N = 4,030 Cognitive decline +(ApoE-)
[54] 66+/W 2006 US Cohort N = 6,314 Cognitive function and decline +
[55] Mean age:
~75/B
2006 US Cohort N = 2,786 Incident dementia +(both whites and blacks)
[56] 55+/B 2006 China Cross-sectional N = 34,807 Prevalent AD and VaD +(AD)
[57] 50+/B 2006 China Cross-sectional N = 16,095 Prevalent dementia and AD +
[58] 65+/B 2007 Guam Cross-sectional N = 2,789 Prevalent dementia and AD +
[59] 64-81/B 2007 The Netherlands Cross-sectional N = 578 Cognitive function +
[60] 60-64/B 2009 Australia Cohort N = 416 Cognitive decline 0
[61] 30-64/B 2009 US Cross-sectional N = 1,345 Cognitive function +(literacy better predictor)
[62] 65-96/B 2009 Spain Cross-sectional N = 1,074 Prevalent dementia +
[63] 80+/B 2009 UK Cohort N = 3,336 Incident dementia +
[64] Mean:72/B 2009 US Cohort N = 6,000 Cognitive function and decline +(cognitive function) 0(cognitive
decline)
[65] 60+/B 2010 Malaysa Cross-sectional N = 2,980 Prevalent dementia +
[66] 55+/B 2010 India Cross-sectional N = 2,466 Prevalent dementia and AD +
[67] 65+/B 2010 Brazil Cross-sectional N = 2,003 Cognitive function +
[68] 60+/B 2011 Brazil Cohort N = 1,461 Cognitive decline -
[69] 60-98/B 2011 Italy Cohort N = 1,270 Incident cognitive impairment +
[70] 60+/B 2011 Mexico Cohort N = 7,000 Prevalent and incident dementia +
[71] 54-95/B 2011 US Cohort N = 1,014 Cognitive decline 0
Study Age/gender Year Country Design Sample size Outcome Finding
(2) Behavioral
(2.1.) Smoking Hypothesis: Current or ever smoking status is associated with lower cognitive function or higher rate of cognitive decline or increased risk of dementia(including AD)
[72] 65+/B 1993 US Cohort N = 1,201 Cognitive decline 0
[73] 65+/B 1994 France Cross-sectional N = 3,770 Prevalent AD, cognitive impairment 0
[74] 74+/B 1996 US Cohort N = 647 Cognitive function 0
[75] Mean:58.6/M 1997 US Cohort N = 3,429 Cognitive impairment +
[36] 69-74/M 1997 Sweden cross-sectional N = 504 Cognitive function +



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[77] adults/B 1998 US Cohort N = 1,469 Cognitive function 0
[78] 55+/B 1998 US Cohort N = 6,870 Incident dementia and AD +(ApoE4−)
[79] 56-69/M 1999 US Cross-sectional N = 569 Cognitive impairment +(ApoE4−)
[80] 45-59/M 1999 UK Cross-sectional N = 1,870 Cognitive function 0
[81] 65+/B 2000 UK Cohort N = 889 Cognitive Impairment +
[82] Mean: 81/M 2000 UK Cohort N = 34,439 Definite or probable AD 0
[83] 45-70/B 2002 Netherlands Cohort N = 1,927 Cognitive change +
[84] 65+/B 2003 Taiwan Cohort N = 798 Cognitive decline 0
[85] 43-53/B 2003 UK Cohort N = 3,035 Cognitive decline +
[86] Mean:78/M 2003 US Cohort N = 3,734 Incident AD +
[87] 60+/B 2003 China Cross-sectional N = 3,012 Cognitive impairment +
[88] 60+/B 2004 China Cohort N = 2,820 Incident dementia and AD +
[89] 65+/B 2004 European cohorts Cohort N = 17,610 Cognitive decline +
[90] 65-84/B 2004 Italy Cohort N = 5,632 Mild cognitive impairment 0
[91] 40-80/M 2004 The Netherlands Cross-sectional N = 900 Cognitive function 0
[92] Mean:75/B 2005 US Cohort N = 791 Cognitive function and decline +(75 + and ApoE4−)
[93] 40-44/B 2005 US Cohort N = 8,845 Incident dementia +
[94] 50+/B 2006 UK Cohort N = 2,000 Cognitive function +
[95] 55+/B 2007 The Netherlands Cohort N = 6,868 Incident dementia and AD +
[96] 43-70/B 2008 The Netherlands Cohort N = 1,964 Cognitive decline +
[97] 35-55/B 2008 France Cohort N = 4,659 Cognitive function +(memory)
[98] 46-70/B 2009 US Cohort N = 11,151 Incident dementia +
[99] 65+/B 2009 US Cohort N = 1,557 Cognitive decline +
[100] 90-108/B 2009 China Cross-sectional N = 681 Cognitive impairment +(men)
[63] Mean:83.5/B 2009 UK Cohort N = 3,336 Incident dementia 0
[101] 65-79/B 2010 Finland Cohort N = 1,449 Incident dementia and AD +
[102] Mean:71.8/B 2010 Taiwan Cohort N = 1,436 Incident cognitive impairment -
[103] 50y/M 2011 Sweden Cohort N = 2,268 Incident dementia and AD +(non-AD)
[104] Mean:60.1/B 2011 Finland Cohort N = 21,123 Incident dementia and AD +



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
Study Age/gender Year Country Design Sample size Outcome Finding
(2.2.) Alcohol Hypothesis: Moderate alcohol consumption is protective against poorer cognitive function, higher rate of cognitive decline and dementia
[106] 65+/B 1996 US Cross-sectional N = 2,040 Cognitive function +(J-shaped)
[107] 59-71/B 1997 France Cross-sectional N = 1,389 Cognitive function + (women)
[76] 75+/B 1998 Australia Cohort N = 327 Incident dementia and AD 0
[77] 40-80/B 1998 US Cohort N = 1469 Cognitive function 0
[108] 55-88/B 1999 USA Cohort N = 1786 Cognitive function +(U-shaped)
[109] 65+/B 2001 US Cross-sectional N = 1,836 Cognitive function +(U-shaped for men, linear for
women)
[110] Mean:70/B 2001 Italy Cross-sectional N = 15,807 Cognitive impairment +(U-shaped)
[83] 45-70/B 2002 Netherlands Cohort N = 1,927 Cognitive change +(women >men) (J-shaped)
[111] 18+/B 2000 US Cohort N = 1,448 Cognitive decline +(women >men) (U-shaped)
[112] 53/B 2003 US Cross-sectional N = 10,317 Cognitive function 0
[87] 60+/B 2003 China Cohort N = 3,012 Cognitive impairment -
[113] 65-79/B 2004 Finland Cohort N = 1,464 Cognitive function +(U-shaped) - (ApoE4+)
[114] 65+/B 2004 US Cohort N = 4,417 Cognitive function +(current drinker vs. former or
abstainer)
[115] 35-55/B 2004 UK Cohort N = 10,308 Cognitive function +(linear, some cognitive
domains)
[116] 65+/B 2005 US cohort N = 1,624 Cognitive function +(current drinker vs. former or
abstainer)
[117] Mean:74/B 2005 US Cohort N = 1,098 Cognitive function and decline +(J-shaped)






Australia Cross-sectional N = 7,485 Cognitive function J-shaped + (light drinkers
vs. abstainers)
[120] 70-81/W 2005 US Cohort N = 11,102 Cognitive function and decline +(J-shaped) (cognitive
decline)
[121] 65-89/M 2006 US Cross-sectional N = 760 Cognitive function +(linear, J-shaped)
[122] 40+/B 2006 US Cohort N = 1,428 Cognitive decline +(linear)
[123] 65-79/B 2006 Finland Cross-sectional N = 1,341 Cognitive function +(linear)
[124] 65-84/B 2007 US Cohort N = 1,445 Incident MCI and MCI→ dementia +(U-shaped)
[125] 50+/B 2010 China Cohort N = 30,499 MCI→ dementia +(J-shaped)




















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[127] 65+/B 2009 China Cross-sectional N = 314 Cognitive impairment +(U-shaped)
[128] 70/B 2011 UK Cross-sectional N = 922 Cognitive function +(linear, verbal memory)
[129] 55+/B 2011 US Cohort N = 1,337 Cognitive function 0 -(executive function)
[130] 55+/B 2011 France Cross-sectional N = 4,073 Cognitive function -(high alcohol use, Low SES)
[131] 45+/B 2012 US Cohort N = 571 Cognitive decline +(heavy drinking)
Study Age/gender Year Country Design Sample size Outcome Finding
(2.3.) Physical
activity
Hypothesis: Physical activity is protective against poorer cognitive function, higher rate of cognitive decline and dementia(including AD)
[132] 70+/B 2001 Hong Kong Cohort N = 2030 Cognitive impairment +
[133] 65+/B 2001 Canada Cohort N = 4615 Incident cognitive impairment
and AD
+
[134] 65-84/M 2001 Netherlands Cohort N = 347 Cognitive decline +(ApoE4+)
[135] 65+/F 2001 US Cohort N = 5,925 Cognitive decline +
[136] 75+/B 2003 US Cohort N = 469 Incident dementias (AD, VaD and
others)
+
[137] 71-93/M 2004 US Cohort N = 2257 Incident dementia and AD +
[138] 65+/B 2004 US Cohort N = 1146 Cognitive decline +
[139] 80+/M 2004 European countries Cohort N = 295 Cognitive decline +
[140] 70-81/W 2004 US Cohort N = 18766 Cognitive decline +
[141] 65+/M 2005 US Cohort N = 3375 Incident dementia and AD +(ApoE4-)
[142] 65-79/B 2005 Sweden Cohort N = 1449 Incident dementia and AD +
[143] 65+/B 2005 US Cohort N = 4055 Cognitive decline -
[144] 75+/B 2006 Sweden Cohort N = 776 Incident dementia +
[145] 65+/B 2006 US Cohort N = 1740 Incident dementia and AD +
[146] 65+/W 2010 US Cross-sectional N = 9344 Cognitive impairment +
[147] 60+/B 2008 Greece Cohort N = 732 Cognitive impairment +
[148] 71-92/M 2008 US Cohort N = 2263 Dementia +
[149] 70+/B 2009 Italy Cross-sectional N = 668 Cognitive decline +
[100] 90-108/B 2009 China Cross-sectional N = 681 Cognitive impairment +
[150] 65+/B 2009 US Cohort N = 1880 Incident AD +
[151] 70-79/B 2009 US Cohort N = 2509 Cognitive function and decline +
[152] Mean:51y/B 2010 Iceland Cohort N = 4945 Cognitive function and dementia +
[153] 55+/B 2010 Germany Cohort N = 3903 Incident cognitive impairment +



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[155] 65+/W 2010 US Cross-sectional N = 9344 Cognitive function and impairment +
[156] Mean:82/B 2012 US Cohort N = 716 AD Cognitive decline +
[157] 40-84/B 2012 US Cohort N = 405 (40–59 years) N = 342 (60–84
years)
Cognitive function +
[158] 65+/B 2012 US Cohort N = 2491 Incident dementia & AD +




Hypothesis: Caffeine consumption is protective against poorer cognitive function, higher rate of cognitive decline and dementia
[159] 18+/B 1993 UK Cross-sectional N = 9,003 Cognitive function +(caffeine)
[160] Mean: 73/B 2002 US Cross-sectional N = 1,528 Cognitive function 0(coffee)
[161] 24-81/B 2003 The Netherlands Cohort N = 1,376 Cognitive change 0(caffeine)
[162] 70+/B 2006 Japan Cross-sectional N = 1,003 Cognitive impairment +(green tea)
[163] Mean ~ 75/M 2007 Finland, the Netherlands
and Italy
Cohort N = 667 Cognitive decline +(coffee, J-shaped)
[164] 55+/B 2008 Singapore Cohort N = 1,438 Cognitive impairment and decline +(tea)
[165] 65-79/B 2009 Finland Cohort N = 1,409 Incident dementia and AD +(coffee), 0(tea)
[100] 90+/B 2009 China Cross-sectional N = 681 Cognitive impairment +(tea, men)
[166] 65+/B 2009 Finland Cohort N = 2,606 Cognitive function, incident
dementia and MCI
0(coffee)
[167] 70-74/B 2009 Norway Cross-sectiona N = 2,031 Cognitive impairment +(tea)
[168] 17-92/B 2009 UK Cross-sectional N = 3,223 Cognitive function 0(caffeine)
[169] 70/B 2010 UK Cohort N = 923 Cognitive function +(coffee); −(tea)
[170] 55+/B 2010 Singapore Cross-sectional N = 716 Cognitive function +(tea)
[171] 65+/B 2010 France Cohort N = 641 Cognitive decline +(caffeine, women)
[172] 65+/B 2010 Portugal Cohort N = 648 Cognitive decline +(caffeine, women)
[173] 65+/B 2011 US Cohort N = 4,809 Cognitive decline +(caffeine, women)
[174] Mean:54/M 2011 US Cohort N = 3,494 Incident dementia and cognitive
impairment
0(caffeine)
[175] Mean:91.4/B 2012 Singapore Cohort N = 7,139 Cognitive change +(tea)
Study Age/gender Year Country Design Sample size Outcome Finding
(3.2) Antioxidants/
Vitamin E
Hypothesis: Antioxidants, including vitamin E, are protective against poorer cognitive function, higher rate of cognitive decline and dementia(including AD)
[176] 55-95/B 1996 Netherlands cohort N = 5,182 Cognitive function +



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[178] 65+/B 1998 US Cohort N = 633 Incident AD +
[179] 5075/B 1998 Austria Cross-sectional N = 1,769 Cognitive performance +(Vit. E)
[180] 71-93/M 2000 Hawaii Cohort N = 3,385 Incident AD, VaD, MD and OD +(VaD)
[181] 48-67/B 2000 US Cross-sectional N = 12,187 Cognitive performance 0
[182] 55+/B 2002 Netherlands Cohort N = 5,395 Incident AD +
[183] 65+/B 2002 US Cohort N = 815 Incident AD +(Vit. E, ApoE4−)
[184] 65-102/B 2002 US Cohort N = 2,889 Cognitive decline +
[185] 65+/B 2003 US Cohort N = 2,969 Incident dementia Incident AD 0
[186] 70-79/W 2003 US Cohort N = 14,968 Cognitive function +(Vit. E)
[187] 65+/B 2003 US Cohort N = 980 Incident AD 0
[188] 45-68/M 2004 US Cohort N = 2,459 Incident dementia and AD 0
[189] 65+/B 2004 US Cohort N = 4,740 Incident and prevalent AD +
[190] 65+/B 2005 Italy Cross-sectional N = 1,033 Prevalent dementia and cognitive
impairment
+
[191] 55+/B 2005 Netherlands Cross-sectional N = 3,717 Prevalent AD 0
[192] 65-105/B 2005 US Cohort N = 616 Incident Dementia Incident AD 0
[193] 65+/B 2005 Canada Cohort N = 894 Cognitive decline Dementia +
[194] 65+/B 2005 US Cohort N = 3,718 Incident AD Cognitive function +
[195] Mean:73.5/B 2007 France Cross-sectional N = 589 Cognitive function +
[196] 60+/W 2007 US Cohort N = 526 Cognitive impairment +(Vit. E)
[197] 65+/B 2007 US Cohort N = 3,831 Cognitive function +
[198] 65+/B 2008 US Cohort N = 3,376 Cognitive function +
[199] 65+/B 2008 US Cohort N = 2,969 Incident Dementia Incident AD 0
[200] 65+/B 2008 Italy Cohort N = 761 Cognitive impairment +(Vit. E Sub-type)
[201] 70+/W 2010 US Cohort N = 16,010 Cognitive function & decline +(cognitive function)
[202] 70/B 2011 UK Cross-sectional N = 882 Cognitive function 0
Study Age/gender Year Country Design Sample size Outcome Finding
(3.3) Homocysteine Hypothesis: Homocysteine is a risk factor for poorer cognitive function, higher rate of cognitive decline and dementia (including AD)
[203] 55+/B 1999 Netherlands Cohort N = 702 Cognitive function and decline 0
[204] 60+/B 2002 UK Cross-sectional N = 391 Cognitive function +
[205] 55+/B 2002 The Netherlands Cross-sectional N = 1,077 Cognitive function +
[206] Mean:76/B 2002 US Cohort N = 1,092 Incident AD +
[207] 60+/B 2003 US Cross-sectional N = 1,789 Global cognitive function +



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[209] 65+/B 2004 US Cohort N = 679 Incident and prevalent AD 0
[210] Mean:72/B 2005 Turkey Cohort N = 1,249 Incident dementia, AD, MCI 0
[211] 60+/B 2005 US Cross-sectional N = 1,789 Cognitive impairment and
dementia
0
[212] 40-82/B 2005 US Cross-sectional N = 2,096 Cognitive function +(60 + y)
[213] 70-79/B 2005 US Cohort N = 499 Cognitive function and decline +(cognitive function)
[214] 85+/B 2005 Netherlands Cohort N = 599 Cognitive impairment and decline +(with impairment)
[215] 65+/B 2005 Switzerland Cohort N = 623 Incident MCI, dementia, AD and
VaD
+
[216] 60+/B 2005 US Cross-sectional N = 1,789 Cognitive impairment and
dementia
+
[217] Mean:74/B 2005 Italy Cohort N = 816 Incident AD +
[218] 50-70/B 2005 US Cross-sectional N = 1,140 Cognitive function +
[219] 50-85/M 2005 US Cohort N = 321 Cognitive decline +
[220] Mean:62/B 2006 US Cross-sectional N = 812 Cognitive function +
[221] 55+/B 2006 China Cross-sectional N = 451 Cognitive function +
[222] Mean:59/B 2006 The Netherlands Cohort N = 345 Cognitive function +
[223] 65+/B 2007 UK Cohort N = 1,648 Cognitive decline +
[224] 60-101/B 2007 US Cohort N = 1,779 Incident dementia and MCI +
[225] 60-85/B 2007 South Korea Cross-sectional N = 1,215 Prevalent MCI +
[226] 26-98/B 2008 US Cross-sectional N = 911 Cognitive function +(ApoE4+)
[227] 65+/B 2008 Korea Cross-sectional N = 607 Cognitive function +
[228] Mean:72/B 2008 Korea Cohort N = 518 Incident dementia and AD +
[229] Mean:77/B 2009 US Cohort N = 516 Prevalent and incident MCI 0
[230] 38-85/B 2010 Sweden Cohort N = 488 Incident dementia 0
[231] 65+/B 2010 The Netherlands Cohort N = 1,076 Cognitive decline +
[232] Mean:78/W 2011 Germany Cross-sectional N = 420 Cognitive function +
[233] 38-60/W 2011 Sweden Cohort N = 1,368 Incident dementia and AD +
[234] 70-89/M 2012 Australia Cohort N = 4,227 Incident dementia +
[235] 70-89/M 2012 Australia Cohort N = 1,778 Incident cognitive impairment +
Study Age/gender Year Country Design Sample size Outcome Finding
(3.4) n-3 fatty acids Hypothesis: n-3 fatty acids are protective against poorer cognitive function, higher rate of cognitive decline and dementia(including AD)
[236] 69-89/M 1997 Netherlands cohort N = 476 Cognitive impairment & decline 0



















Table 2 Summary of epidemiologic studies of risk and protective factors for cognitive outcomes included in the review (Continued)
[238] 55+/B 2002 Netherlands Cohort N = 5,395 Incident dementia and AD 0
[239] 65-94/B 2003 US Cohort N = 815 Incident AD +
[240] 45-70/B 2004 Netherlands Cross-sectional N = 1,613 Cognitive function +
[241] 65+/B 2005 US Cohort N = 3,718 Cognitive decline 0
[242] 65+/B 2007 France Cohort N = 8,085 Incident dementia and AD +(ApoE4-)
[243] 50+/B 2007 US Cohort N = 2,251 Cognitive decline +(hypertensive, Dyslipidemic)
[244] Mean:76/B 2007 Italy Cross-sectional N = 935 Prevalent dementia +
[245] 50-70/B 2007 Netherlands Cohort N = 404-807 Cognitive function and change +(change)
[246] 50+/B 2008 US Cohort N = 2,251-7,814 Cognitive decline +(hypertensives)
[247] 65-80/B 2008 Finland Cohort N = 1,449 MCI and cognitive function +
[248] Mean:78/B 2008 France Cohort N = 1,214 Incident dementia +
[249] 65+/B 2009 Multi-national Cross-sectional N = 14,960 Prevalent dementia +
[250] 55+/B 2009 Netherlands Cohort N = 5,395 Incident dementia and AD 0
[251] 65+/B 2009 Canada Cohort N = 663 Incident dementia or AD 0
[252] Mean:68/M 2009 Netherlands Cohort N = 1,025 Cognitive function 0
[253] 76-82/W 2009 France Cohort N = 4,809 Cognitive decline +
[254] Mean:75/B 2010 Spain Cross-sectional N = 304 Cognitive impairment +
[255] 35-54/B 2010 US Cross-sectional N = 280 Cognitive function +
[256] 55+/B 2011 Singapore Cohort N = 1,475 Cognitive function and decline +(supplements)
[257] Mean:~64/B 2011 France Cohort N = 3,294 Cognitive impairment +
[258] 65+/B 2011 France Cohort N = 1,228 Cognitive decline +(ApoE4+; depressed)
+Hypothesized association; − Association against hypothesis; 0: No association.




















Figure 1 Flowchart of study selection for systematic review and meta-analysis. Notes: MEDLINE searches (1990–2012) included the
following: (1) “Risk factor” as MESH term AND “Dementia” in title; (2) “Risk factor” as MESH term AND “Alzheimer” in title; (3) “Risk factor” as MESH
term AND “Alzheimer” in title; (4) “Risk factor” as MESH term AND “cognitive” in title; (5) “Risk factor” in title and “cognitive” in title. Given that
each search is not mutually exclusive of other searches, there were duplicates which were deleted from the final number of included studies. The
following notations are defined follows: N1 = Studies excluded from all searches combined due to small sample size; N2 = Studies excluded from
all searches combined due to design being neither cross-sectional nor cohort; N3 = Studies excluded from all searches combined due to being a
review or a letter to the editor; N4 = Studies excluded from all searches combined due to lack of relevance to topic or hypothesis; N5 = Studies
excluded from all searches combined for other reasons (e.g. special group of people); N6 = Final included studies; N6a = Final included cohort
studies; N6b = Final included cross-sectional studies.
Beydoun et al. BMC Public Health 2014, 14:643 Page 13 of 33
http://www.biomedcentral.com/1471-2458/14/643conducted. This analysis was mainly based on the hypoth-
esized direction of association and the final conclusion
of the study. Thus, main findings based on the pre-set
hypothesis was coded (+: supports the hypothesis; 0: no
significant finding; −: against the hypothesis). In addition,
within +, we coded studies as partially supporting the
hypothesis for three main reasons: “some outcomes but
not others”, “some exposures but not others”, “some
sub-group(s) but not others”. These papers are sorted
by risk factor, year of publication and first author’s last
name.Descriptive analysis
In the descriptive part of the analysis, a data point con-
sisted of a study finding within a design/risk factor
dyad (e.g. cohort/education). Using the data points, we
conducted an analysis to assess consistency of positive
findings across risk factors and study designs (cohort
vs. cross-sectional). In particular, we estimated the %
of positive findings for all participants and most out-
comes; % of positive findings for some outcomes or
exposures but not others; % of positive findings for
sub-groups; % null findings; % of findings against hy-
pothesized direction. In addition, study-level charac-
teristics (e.g. year and country of publication, study
design, type of cognitive outcome, sample size, age
group, sex) were described in detail and compared
across risk factors, using χ2 test, independent samples
t-test and one-way ANOVA.Consistency analysis: all data points
In this part of the analysis, we modeled study finding
as a binary outcome coded as 0=”null finding or find-
ing against hypothesized direction” (referent category),
1=”positive or partially positive finding”, as a function
of study-level characteristics using a logistic regression
model. The study-level characteristics were entered as
main effects as follows: (1) Year of publication; (2)
Country of publication (1 = US, 2 = European country,
3 = Others), (3) risk factor (1 = education, 2 = smoking,
3 = alcohol, 4 = physical activity, 5 = caffeine, 6 = antioxi-
dants, 7 = homocysteine, 8 = n-3 fatty acids); (4) sample
size (when a range was provided, the average was taken),
(5) Study participant age group: 1 = contains ages <65y,
0 = does not contain ages <65y; (6) Participant gender
composition: 1 =Men only; 2 =Women only; 3 = Both;
(7) Study design: 1 = cross-sectional; 2 = cohort; (8)
Number of cognitive outcomes included in the study (e.g. 1
if only incident AD was the outcome; 2 if it is both incident
AD and incident dementia); (9) General category of
cognitive outcome(s): 1 = dementia/AD/impairment; 2 =
cognitive function/decline; 3 = both.Meta-analysis: data points with incident AD and selected
risk or protective factors
Focusing on data points with incident AD as an outcome,
we conducted further meta-analysis to assess the strength
of the association between selected risk or protective fac-
tors and this outcome. This analysis was thus restricted to
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had comparable measurements for each risk/protective
factor, thus allowing to estimate a pooled measure of asso-
ciation across those data points and studies. The original
reported odd ratios (ORs), relative risks (RRs) or Hazard
Ratios (HRs) were combined into a pooled value with 95%
confidence interval (CI). The RRs were then pooled using
random effects models when included study data points
were deemed heterogeneous based on the Q-test for
homogeneity (p < 0.05) or fixed effect when study data
points were homogenous (p > 0.05), which are also pre-
sented among results. As such, a summary or pooled
RR was provided using forest plots and computed by
computing the weighted average of the natural logarithm
of each relative measure of interest weighting by the
inverse of each RR’s respective variance [260]. Random
effects models that further incorporated between-study
variability were conducted using DerSimonian and Laird’s
methodology.
Considering estimates of exposure prevalence from the
largest study with available data on each exposure, we
also computed a population attributable risk percentage
(PAR%) by pooling data points from all studies together.
PAR%p;lcl;ucl;ij ¼
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PAR%95%CI; ij ¼ PAR%p;ij  1:96
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Var θij
 q  100 ð1:3Þ
As shown in Equations 1.1, 1.2 and 1.3, RR (point
estimates per study and data point; 95% CI) was applied
to the formula and Prexp was the estimated prevalence of
each exposure. The estimation of SE for PAR% was
obtained using the delta method [261].
Finally, in order to examine publication bias, we used
Begg’s funnel plots; each RR point estimate was plotted
against their corresponding standard errors (SE) for each
study on a logarithmic scale [262,263], for all exposures
combined. This type of bias was also formally tested
using the Begg-adjusted rank correlation tests [264] and
the Egger’s regression asymmetry test [265]. All analyses
were conducted with STATA 11.0 (StataCorp, College
Station, TX) [266]. Type I error was set at 0.05 for all
measures of association.
Results and discussion
Socio-economic Status (SES) as indicated by education
Early life conditions are related to cognitive develop-
ment and abilities in childhood and cognitive functionin adulthood. Low educational attainment and other
markers of low socio-economic position (SEP) were as-
sociated with poorer cognitive function in adulthood
and age-related cognitive decline and impairment, as
well as greater risk or prevalence of dementia and AD
in the elderly. In this study, we focused our attention
on education as a maker of SES, given that it is the
most commonly studied protective factor.
Several possible mechanisms support the finding that
less education is related to cognitive decline: First, educa-
tion may exert direct effects on brain structure early in life
by increasing synapse number or vascularization and
creating cognitive reserve. This was named the “reserve
capacity” hypothesis. Thus, this hypothesis states that
early life conditions affect the pace of cognitive decline
in later life [38]. Education in early life may have effects
in later life if persons with more education continue
searching for mental stimulation (“the use it or lose it”
hypothesis), which may lead to beneficial neurochemical
or structural alterations in the brain [267]. Indeed, in
one study, recent mental stimulation was associated
with improved cognitive functioning [268]. Alternatively,
education may act through several “behavioral mediators”
to improve health in general, and cognitive functioning in
particular [267]. This hypothesis was confirmed by a study
using the Framingham cohort which suggested that
education was uniquely protective against VaD and not
associated with AD [28]. This finding was explained by
mediating effects of other risk factors of cognitive decline,
including smoking and hypertension, which in turn can
initiate cerebrovascular damage. However, Lee and col-
leagues [52] found evidence contrary to this hypothesis by
showing a sustained strong association between education
and cognitive functioning after adjustment for behavioral
and health-related factors.
Based on our findings (Table 2 and Figure 2A), 18
(66.7%) of the 27 cohort studies that met our selection
criteria found that lower education was linked to a worse
cognitive outcome in the overall population and for all
studied outcomes, 1 found this relationship with incident
VaD but not AD [28], 1 found the relationship with cogni-
tive function but not decline [64], 1 concluded that IQ was
a better predictor than education [38], and 2 detected a
significant association in the hypothesized direction only
in women [44] and in ApoE4- individuals [53]. The
remaining four cohort studies did not find an association
in the hypothesized direction [26,60,68,71].
Note: +(ALL) = positive finding, given hypothesis, for
all subjects and most outcomes of interest; +(some out-
comes) = positive finding, given hypothesis, for all subjects
and some outcomes of interest but not others; +(some
groups) = positive finding, given hypothesis, for some
groups and most outcomes of interest; 0 = null finding,
given hypothesis; − = finding against hypothesized direction.
Figure 2 Main findings (%) of selected studies, given hypothesis: (A) Cohort Studies (B) Cross-sectional studies.
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factor and finding.
The association between education and the studied
cognitive outcomes was in the hypothesized direction,
with higher education being protective, for the majority
of the selected cross-sectional studies (21 out of 25,
84%), while 2 found an association with prevalent AD
but not VaD [41,56], 1 found that literacy was a better
predictor than education [61], and 1 failed to detect a
significant association [40] (See Table 2 and Figure 2B).
Behavioral factors
Several behavioral factors were selected, including smoking,
alcohol drinking,and physical activity.
Smoking
Smoking is a risk factor for several chronic diseases, but its
long-term relationship with dementia of various sub-types
is still controversial. In fact, smoking is well known to
increase the risk of stroke [269] and thus subsequent
vascular types of dementia (VaD). However, many studieshave concluded that smoking status influenced risk of
VaD independently of stroke status and thus may have an
effect beyond cerebrovascular disease. In addition, studies
that have shown a direct impact of smoking on AD,
suggest that smoking might in fact influence neurode-
generation. A vast amount of literature points to a role
of smoking in oxidative stress and inflammation, both
mechanisms believed to play a key role in AD [270].
However, it is also biologically plausible that smoking
might protect against cognitive decline and AD, given
that nicotine, a key active component of tobacco, may
enhance the release of acetylcholine, increase the density
of nicotnic receptors, therefore improving attention and
information processing [271]. It is now known that AD
is characterized by cholinergic system deficits which
may be delayed through tobacco consumption [271,272].
Population-based evidence of an effect of smoking
on cognitive outcomes was inconclusive, with most
longitudinal studies reporting weak or null associa-
tions [63,72,74,76,77,82,84,90]. However, a number of
other cohort studies have found a positive association
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[78,86,88,93,95,98,101,103,104] as well as incident cogni-
tive impairment [75,81,90] and age-related cognitive de-
cline [83,85,89,96,99,105].
For instance, the British 1946 birth cohort study pointed
to the difficulty of finding an association between smoking
and cognitive impairment given the differential high mor-
tality of smokers especially among the elderly population
[85]. After controlling for a range of socioeconomic and
health status indicators (both physical and mental), they
found that smokers who survive into later life may be at
risk of clinically significant cognitive decline. However,
these effects were accounted for largely by heavy smokers,
i.e. those who smoked 20 cigarettes per day or more.
Earlier research on middle aged adults suggested that
current smoking and number of pack-years of smoking
were related to reduced performance on tests of psycho-
motor speed and cognitive flexibility assessed approxi-
mately five years later [83]. Similar results were shown
for cognitive decline in a large cohort study (Rotterdam
study) conducted in multiple European countries [89]
and in another more recent study conducted in the
United States [92].
Among studies that examined incidence of AD in relation
to smoking status, two of the largest European cohort
studies reported conflicting results. While one found no
relationship between smoking status and incident AD
among a large sample of 34,439 older UK men (mean
age: 81) [82], the recent 2011 study found that heavy
smoking increased the risk of dementia and AD in a
younger sample of 21,123 older Finnish adults (Mean
age:60.1) that comprised both men and women [104].
In sum, 16 (55.2%) out of the 29 selected cohort studies
linking smoking to the various cognitive outcomes found
the relationship to be in the hypothesized direction in the
entire population that was studied and for most outcomes
of interest [75,81,83,85,86,88,89,92-96,98,99,101,104], while
2 found this relationship for some outcomes but not others
[97,103] and 2 detected it for a sub-group of the total
population [78,105], while the remaining 9 studies did not
find an association [63,72,74,76,77,82,84,90] or found an
association in the opposite direction [102]. (See Table 2
and Figure 2A).
Only 2 (28.6%) of the 7 cross-sectional studies found an
association in the hypothesized direction [36,87], while 2
detected it for a sub-group of the total population
[79,100], and the remaining 3 did not detect a significant
association [73,80,91], (See Table 2 and Figure 2B).
Alcohol
Alcohol consumption in moderation was hypothesized to
be protective against cognitive decline and impairment in
old age. Several mechanisms may be involved in explain-
ing the potential protective effect of moderate alcoholconsumption on various cognitive outcomes. First, this ef-
fect might be mediated through cardiovascular risk factor
reduction, partly through a dampening effect of ethanol
on platelet aggregation, or through a modification of the
serum lipid profile. Second, another potential mechanism
in which alcohol can have a direct effect on cognitive
function is through acetylcholine release in the hippocam-
pus, which in turn enhances learning and memory [273].
The Rotterdam study [83] also examined the effect of
alcohol use on cognition. They found that past alcohol
consumption’s effect on speed and flexibility appeared to
be slightly U-shaped, with the best performance observed
among those who drank 1–4 glasses of alcohol per day, al-
though this association was stronger among women than
among men. Other studies also detected sex differences
[106,107,111]. Light to moderate alcohol consumption was
also found beneficial based on findings of other cohort
and cross-sectional studies with a U- or J-shaped pattern
observed [108-110,113,114,116,117,119-121,124-127]. How-
ever, in other studies, a linear dose–response relationship
between alcohol use and improved cognition was noted,
though the authors cautioned that these should not en-
courage increased alcohol consumption without an upper
bound to this consumption [114,115,122,131].
In one cross-sectional study, a linear relationship between
alcohol consumption and cognitive function was found in
women but a U-shaped pattern was found in men [109].
One cohort study found that overall, moderate consump-
tion was protective against poor cognitive function, but had
an opposite relationship with cognitive function among
ApoE4+ individuals [113], while another found that alcohol
use in general was related to better cognition without effect
modification by ApoE4 status [123]. Slower memory
decline with increased alcohol consumption in men was
found in one study, though the opposite relationship was
found in the case of psychomotor speed among women
[118]. The positive association between alcohol intake and
memory was also noted in at least one other cross-
sectional study for both men and women combined [128].
Moreover, heavy alcohol use was linked to poorer cogni-
tive outcomes in a few studies [87,127,129,130]. Finally,
only a few studies among those that were selected found
no associations between alcohol consumption and cogni-
tive outcomes [76,77,112].
In fact, 8 out of the 18 selected cohort studies (44%)
linking alcohol consumption to the various cognitive
outcomes, found the relationship to be in the hypothe-
sized direction (but were U-shaped, J-shaped or linear)
in the entire population that was studied and for most
outcomes of interest [108,114,116,117,122,124,125,131],
while 2 found this relationship for some outcomes but
not others [115,120] and 4 detected it for a sub-group of
the total population [83,111,113,118]. Moreover, 1 cohort
studies have indicated that alcohol use was generally linked
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[87]. Finally, 3 did not find any significant associations
between alcohol consumption and the various cognitive
outcomes that were under study [76,77,129]. (See Table 2
and Figure 2A).
9 of the 12 cross-sectional studies (75%) found an as-
sociation in the hypothesized direction for the entire
study population and for most outcomes of interest
[106,109,110,119,121,123,126-128]. The remaining 3
studies either found this U-shaped or J-shaped association
in a sub-group [107], and either failed to detect any asso-
ciation [112] or detected one that was not in line with the
hypothesis, whereby alcohol use was generally found to
result in poor cognitive outcomes [130]. (See Table 2 and
Figure 2B).
Physical activity
Physical activity has many well-known benefits for pre-
venting a number of chronic disorders, including coronary
heart disease, stroke, diabetes mellitus and osteoporosis.
However, its impact on cognitive functioning has not been
studied extensively. Several mechanisms may underlie the
potentially protective effects of physical activity on cogni-
tive function, including sustained cerebral blood flow
[274], improved aerobic capacity and cerebral nutrient
supply [275,276] as well as growth factors, specifically the
brain-derived neurotropic factor, which is a molecule that
increases neuronal survival, enhances learning, and pro-
tects against cognitive decline [277,278].
Currently, 24 cohort and 4 cross-sectional studies have
examined the hypothesized relationship. For instance, a
recent cohort study of 716 dementia-free older adults
from the Rush Memory and Aging Project who were
followed-up for an average of 4 years found an inverse
relationship between total daily physical activity and
incident AD after controlling for age, sex, education,
self-report physical, social, and cognitive activities, as
well as current level of motor function, depressive symp-
toms, chronic health conditions, and ApoE4 allele status
[156]. Furthermore, a recent cross-sectional study of 9344
women, 65 years and older, found a lower prevalence of
cognitive impairment among those who reported being
physically active versus those who reported being physic-
ally inactive at different stages of their lives [155].
These findings suggested that physical activity could
represent an important and potent protective factor for
cognitive decline and dementia in elderly persons. Sig-
nificant findings were obtained by other recent cohort
[132-145,147,148,150-154,156-158] and cross-sectional
studies [100,146,149]. Only one cohort study resulted
in non-significant findings [143].
In sum, of the 24 selected cohort studies linking phys-
ical activity to the various cognitive outcomes, 21(87.5%)
found the relationship in the hypothesized direction in theentire population that was studied and for most outcomes
of interest [132,133,135-140,142,144,145,147,148,150-154,
156-158,279], while 1 found this relationship in ApoE4 car-
riers [134] and 1 in non-carriers [141]. In one cohort study,
the association was against its hypothesized direction
[143]. (See Table 2 and Figure 2A).
In addition, all 4 of the selected cross-sectional studies
(100%) found an association in the hypothesized direction
for the entire study population and for most outcomes of
interest (See Table 2 and Figure 2B).
Nutritional factors
Nutritional factors being studied in relation to cognitive
outcomes included caffeine consumpion, antioxidant nu-
trients and Hcy. In addition, special attention was devoted
recently to one class of essential fatty acids, namely n-3
fatty acids.
Caffeine
Caffeine is known to be the most widely used psychoactive
drug worldwide. Its main source is coffee particularly
in Western diets. Acting as a stimulant of the central
nervous system, caffeine causes heightened alertness and
arousal [280]. Previous literature yielded inconsistent find-
ings about the effects of caffeine consumption on cogni-
tive processes. In fact, caffeine improved perceptual speed
and vigilance, as well as more complex functions such as
memory [281]. Caffeine is one type of compound known
as methylxanthines whose effects are mainly to block ad-
enosine receptors in the brain, resulting in cholinergic
stimulation. It was hypothesized that such stimulation
would lead to improved memory [282]. The earliest large
cross-sectional study conducted by Jarvis and colleagues
found that caffeine improved cognitive performance [159].
Later on, other cross-sectional studies focusing on tea con-
sumption found similar results [100,162,167,170]. Others,
however, did not show evidence of a significant protective
effect [160,168]. In sum, 4 of 7 selected cross-sectional
studies linking caffeine consumption to various cognitive
outcomes found the relationship to be in the hypothesized
direction in the study population and for most outcomes of
interest (57.1%), one found this association in men [100]
and two failed to find a significant association [160,168].
(See Table 2 and Figure 2B).
Of 11 cohort studies, positive findings pertained to 3
(27.3%) [163,164,175], though this was found only for
coffee intake in two studies [165,169], while 5 recent
studies detected this association only among women or
for specific exposures [165,169,171-173]. The remaining
cohort studies (3 of 11, 27%) did not find an association
between caffeine intake and cognitive change [161] or
incident dementia [166,174]. Given the paucity of large
cohort studies, more research is needed to establish
causality (See Table 2 and Figure 2A).
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Several findings suggest that oxidative stress may play an
important role in the pathogenesis of AD. First, the
brains of AD patients have lesions that are associated
with exposure to free radicals. Moreover, oxidative stress
among these patients is also marked by an increased level
of antioxidants in the brain that act as free radical scaven-
gers. Finally, in vitro studies suggest that exogenous antioxi-
dants may reduce the toxicity of β-amyloids in the brains of
AD patients [283-285]. Based on these findings, it may be
hypothesized that dietary antioxidants may help reduce the
risk of AD.
Those epidemiologic studies examined the longitudinal
relationship between supplemental antioxidants and risk
of AD and other dementias found conflicting results:
While vitamin C supplement use was related to lower AD
risk in one cohort study [178], combined supplementation
of vitamin E and vitamin C was associated with reduced
prevalence and incidence of AD and cognitive decline in
three other cohort studies [189,193,198], whereas another
study found this effect to be specific to Vitamin E supple-
ments [186]. These findings of a protective effect of sup-
plemental antioxidant use against cognitive impairment
and decline was replicated in a large cohort study [185].
However, there were only borderline or little evidence of a
cognitive benefit from use of antioxidant supplements,
particularly vitamins C and E, according to at least five
independent cohort studies [177,180,187,192,199].
There are several prospective cohort studies on the effect
of dietary antioxidants on the risk of dementia. One study
found that high dietary intake of vitamins C and E may
reduce the risk of AD [182] with the relationship most
pronounced among smokers. Morris and colleagues [183]
found that dietary intake of vitamin E, but not other anti-
oxidants, was associated with a reduced risk of incident
AD, although this association was restricted to individuals
without the Apolipoprotein E ε4 genotype. Similar find-
ings were reported with cognitive decline as an outcome
[184]. In a later study when both outcomes were consid-
ered it was concluded that certain forms of tocopherols
not found in dietary supplements but found only in foods
may be at play [194]. This observation was corroborated
by at least one recent study [197]. Another study, however,
suggested that dietary antioxidants were not able to re-
duce AD risk [187]. Similarly, Laurin and colleagues
[188] found no association between midlife dietary intake
of vitamins E and C and dementia incidence. At least
five other cohort studies came to a similar conclusion
[176,181,201,202]. In addition to examining associations
of cognition with vitamins C and E, other studies found
that carotenoids, particularly β-carotene intake, may
be have beneficial effects of various cognitive outcomes
[176], though others were not able to detect such an
association [184,201,202].Irrespective of the source of antioxidants, plasma
concentration may be a good biomarker for oxidative
stress status. In particular, an inverse association between
plasma vitamin E among others and poor cognitive out-
comes was found in at least two cross-sectional studies
[179,190] and two cohort studies [196,200]. Another
cross-sectional study, however, did not find evidence of
an association between plasma antioxidants, including
vitamin E and prevalent AD [191]. In addition, among
studies that examined the influence of plasma carotenoids
[179,195], only one detected a significant potential pro-
tective effect against cognitive impairment [195]. While
these results are mixed, they suggest that at least one anti-
oxidant has a protective effect against adverse cognitive
outcomes.
In sum, of the 21 selected cohort studies linking anti-
oxidants, with focus on vitamin E, to the various cogni-
tive outcomes, 9 (42.9%) found the relationship to be
in the hypothesized direction in the entire population
that was studied and for most outcomes of interest
[176,178,182,184,189,193,194,197,198], while 5 found this
relationship for specific antioxidants or some outcomes
but not others [180,183,186,196,200,201] and 1 detected it
for a sub-group of the total population [183]. The
remaining selected cohort studies (n = 6) did not find a sig-
nificant association [177,185,187,188,192,199]. (See Table 2
and Figure 2A).
Similarly, of the 6 cross-sectional studies that were
selected, 2 (33.3%) found an association in the hypothe-
sized direction for the entire study population and for most
outcomes of interest [190,195], 1 found the association to
hold only for vitamin E [179], whereas 3 found no signifi-
cant association [181,191,202]. (See Table 2 and Figure 2B).
Homocysteine
An elevated level of plasma concentration of the sulfur
amino acid Hcy (hyperhomocysteinemia) is recognized as
an independent risk factor for cardiovascular, peripheral
vascular, and cerebrovascular disease [286]. Accordingly, a
potential influence of hyperhomocysteinemia on cognitive
functioning among older adults was postulated and
several studies were able to associate high levels of Hcy
with increased risk of incident AD or all-cause dementia
[206,217,224,228,233,234]. Studies have pointed to se-
lective effect of Hcy on specific domains of cognition
[214,287,288]. One explanation could be that Hcy might
be affecting certain parts of the brain to a greater extent
than others, and studies have linked Hcy to higher degree
of white matter hyperintensities and with brain atrophy
[289-293].
Even though blood Hcy levels increase with age and
diminished renal function, it is largely determined by
dietary intake of B-vitamins (mainly B-6 and B-12) and
folate which are needed to convert Hcy into methionine
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Thus, Hcy status in plasma can be modified by dietary
interventions. Moreover, vitamin B-12 plasma level has
been shown to be inversely related to that of Hcy [295]
and studies looking at Hcy levels and cognitive function-
ing also examined the effect of B-vitamins. In particular,
vitamin B-12 was found to be protective against decline in
at least three recent studies [204,213,219]. At least five
other studies [204,213,214,216,217,219,221] concluded
that fotate was protective against cognitive impairment or
decline. For Vitamin B-6, two other studies suggested a
protective effect [213,219]. An antagonistic interaction of
folate and Vitamin B-12 with Hcy’s effect on cognition
was noted in other studies [224,296,297]. Aside from its
link to cardiovascular disease, Hcy was shown to have
neurotoxic and excitotoxic properties in vitro [298,299],
suggesting a direct influence on cognition.
Overall, of the 19 selected cohort studies linking Hcy
to the various cognitive outcomes, 12(63.2%) found the
relationship in the hypothesized direction in the entire
population that was studied and for most outcomes of
interest [206,215,217,219,222-224,228,231,233-235], while
2 found this relationship for some outcomes but not
others or a sub-group [213,214] and 5 were not able to
detect a significant association [203,209,210,229,230].
(See Table 2 and Figure 2A).
Similarly, of the 14 cross-sectional studies that were
selected, 11(78%) found an association in the hypothe-
sized direction for the entire study population and for
most outcomes of interest [204,205,207,208,216,218,
220,221,225,227,232], 1 found an association only among
older adults above age 60y [212], 1 detected it among
ApoE4+ individuals [226], and 1 found no significant re-
lationship [211]. (See Table 2 and Figure 2B).
n-3 fatty acids
Another nutritional factor hypothesized to be protective
against cognitive decline is higher intake of n-3 fatty
acids and/or a better balance of n-3/n-6 fatty acids.
Linoleic(LA ~ 18:2n-6) and α-linolenic (LNA ~ 18:3n-3)
are two types of fatty acids that are essential for all
members of the animal kingdom. These fatty acids and
their respective derivatives are also commonly referred
to as n-6 and n-3 fatty acids. Their essentiality lies in the
fact that they cannot be synthesized de novo within the
human or animal organism [300].
In the past, n-3 fatty acids were classified only as es-
sential because of their ability to alleviate deficiency
symptoms that include dermatitis, growth retardation
and reproductive failure. However, n-3 fatty acids have
other important neurological functions, which explain
their high concentrations in neural and retinal tissues
[301-303]. Some of the longer chain fatty acids that are
synthesized from α-linolenic acid include Eicosapentanoicacid (EPA ~ 20:5 n-3), which through further elongation,
desaturation and β-oxidation produces Docosahexaenoic
acid (DHA~ 22:6 n-3). On the other hand, products of
linoleic acid which are also termed long-chain n-6 fatty
acids include gamma-linoleic (GLA ~ 18:3 n-6), dihomo-
gammalinolenic acid (DGLA ~ 20:3 n-6) and Arachidonic
acid (AA ~ 20:4 n-6) [304]. Of all organs in the human
body (excluding adipose tissue), the nervous system
has the highest lipid content. The dry weight of an
adult brain is 50% to 60% lipid, and 35% of the lipid
content is accounted for by polyunsaturated fatty acids
(PUFAs) [305].
A review of scientific articles and biochemistry text-
books [306] suggested that the fatty acid composition of
neuronal cell membrane phospholipids reflects their
intake in the diet. Fish oils, which contain high levels of
C20 and C22 PUFA, exert the most profound influence
on brain PUFA concentrations [306]. The ratio between
n-3 and n-6 PUFA may influence various aspects of
serotoninergic and catecholaminergic neurotransmission,
and it has been shown that by increasing the density
of neurotransmitter receptors for acetylcholine and
dopamine, dietary n-3 PUFA can improve learning and
memory processes [307].
Previous observational studies suggested that the
biochemical composition of blood components in terms
of fatty acids differs significantly between subjects with
normal cognitive functioning and patients with some form
of cognitive impairment. While the majority of these
studies showed an inverse association of plasma and
erythrocyte n-3 fatty acids with cognition among older
adults [243-245,248,255,258], at least one found no
association between biochemical markers of n-3 fatty
acids and cognition [251].
Epidemiological studies involving self-reported dietary
data of n-3 fatty acids had suggestive but slightly contro-
versial results. One study by Morris and colleagues used
cohort data on 815 subjects who were initially unaffected
by AD (age range: 65-94y, mean follow-up period = 2.3y).
Using standardized criteria, AD incidence was compared
across n-3 fatty acid consumption groups, with those
eating fish once per week compared to those who rarely
or never eat fish having considerably lower incidence
(RR = 0.4; 95% CI: 0.2, 0.9). Total n-3 fatty acid consump-
tion was also associated with a reduced AD risk even after
controlling for intake of other dietary fats, vitamin E and
for cardiovascular conditions [239]. A similar finding was
reported later on for a larger but comparable cohort when
looking at fish consumption and cognitive decline over
time [241].
In the Zutphen Elderly Study, cognitive functioning
and decline over three years were assessed in a cohort of
476 men aged 69-89y using the Mini-Mental State
Examination (MMSE). Findings indicated that high linoleic
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ated with cognitive impairment, even after controlling for
age, education, cigarette smoking, alcohol consumption
and energy intake (OR = 1.76, 95% CI: 1.04-3.01, comparing
highest to lowest tertile). However, there was no distinctive
association for n-3 fatty acids. Nevertheless, total fish
consumption was suggestive of a protective effect, even
though it did not reach significance [236].
Another larger cohort study–The Rotterdam Study–
recruited 5,386 non-institutionalized participants, aged
55 + y at baseline, who had normal cognition and assessed
their complete dietary intake with a semi-quantitative
food-frequency questionnaire. After an average 2.1y of
follow-up, lower risk of incident dementia and AD was
found among fish consumers and therefore among
those with higher intake of n-3 fatty acids (RR = 0.3;
95% CI: 0.1-0.9) [237]. However, when the study was
conducted later with a longer follow-up (mean follow-up
period of 6.0 years), it was concluded that high intake of
total, saturated, trans fat, cholesterol and low intake of
monounsatured fatty acids (MUFA), total PUFA, n-6
PUFA and n-3 PUFA were not associated with increased
risk of dementia or its subtypes [238].
A cross-sectional study of 1,613 subjects aged 45–70
years that examined the association between fatty acid
and fish intake with cognitive function, found that the
risk of cognitive impairment was reduced with increased
consumption of fatty fish and marine n-3 PUFA. per
Standard Deviation (SD) increased intake, the ORs were
0.81 (95% CI: 0.66, 1.00) and 0.72 (95% CI: 0.57, 0.90),
respectively [240]. Another recent study using the
Athersclerosis Risk in Communities (ARIC) cohort data
suggested that dietary intake of n-3 fatty acids (mainly
DHA + EPA) reduced the risk of cognitive decline in ver-
bal fluency but not other cognitive domains (i.e. delayed
word recall and psychomotor speed). This protective ef-
fect was particularly strong among hypertensive subjects
[246]. The potentially protective effect of dietary n-3 fatty
acid was also reported in several other large epidemio-
logical studies [242,247,249,253,254,256-258], but not in
others [250-252].
In sum, 7 out of the 18 (39%) selected cohort studies
linking n-3 fatty acids to the various cognitive outcomes
found the relationship in the hypothesized direction in the
entire population that was studied and for most outcomes
of interest [237,239,247,248,250,253,257], while 1 found this
relationship for some outcomes but not others [245], 4 de-
tected it for a sub-group of the total population [242,243,
246,258], and 6 found no association [236,238,241,250-252]
(See Table 2 and Figure 2A). In addition, all of the 5 (100%)
cross-sectional studies that were selected found an as-
sociation in the hypothesized direction for the entire
study population and for most outcomes of interest
[240,244,249,254,255] (See Table 2 and Figure 2B).Description of study-level characteristics and comparison
by risk factor
Table 3 shows descriptive findings of study-level charac-
teristics and compares their distributions across risk
factors. Out of the 247 selected studies, 98 were con-
ducted in the US (39.7%), while 104 were carried out in
a European country (42.1%), and the remaining 45 stud-
ies originated from Asia, Canada and Australia among
others (18.2%). The majority of the selected studies were
cohort studies (n = 167). Most had only one type of
cognitive outcome (72.5%), whereas 24.3% had two, and
the remaining 3.2% had 3 or 4 outcomes. 152 studies
had confirmed positive findings for most outcomes,
exposures and for all study sub-groups (61.5%), while
18.2% (n = 45) had null findings. Partially positive find-
ings were found in around 18.2% while 2% had a finding
against the hypothesized direction. Around 40.5% of
studies included participants with ages <65y, and the
majority had both men and women (84.2%). Incident
AD as an outcome was available in 47 studies, while 47
studies included incident dementia as a main outcome
of interest. On the other hand, cognitive function as an
outcome was found in 83 of included studies, while 62
of those studies had cognitive decline or change as a
primary outcome of interest (data not shown). In general,
there was an almost even split between studies focusing
on cognitive function/decline/change (51.0%) and studies
focused on AD/dementia/impairment as outcomes (46.2%).
Only 2.8% of the studies examined both categories. When
comparing the distribution of those study-level characteris-
tics by risk factor, we found some significant differences for
year of publication, country, age group inclusion/exclusion,
study design, cognitive outcome type and study finding. In
particular, studies on education and cognitive outcomes
tended to be published earlier than studies of other risk
factors, there were significantly more European studies of
n-3 FA compared to other risk factors, while most studies
with PA excluded middle aged adults unlike other risk
factors. The highest proportion of cohort studies was
also found for PA. The vast majority of studies on
alcohol and cognitive outcomes used cognitive function/
decline as their primary outcome of interest, unlike
other risk factors which were more balanced in terms
of cognitive outcome type. The percent positive finding
was highest among PA studies (89.3%) and lowest for
caffeine studies (38.9%). The significant difference in
percent “positive finding” was found in cohort studies
(p = 0.043) rather than cross-sectional studies (p = 0.09)
(See Figure 2A-B).
Consistency analysis: study-level characteristics and risk
factor as predictors of study finding
In an attempt to examine heterogeneity in findings across
risk factors and study-level characteristics, we conducted
Table 3 Study-level characteristics distribution, overall and comparison across risk factors
Overall EDU SMOK ALCO PA CAFF ANTIO HCY N-FA P*
N = 247 N = 52 N = 36 N = 30 N = 28 N = 18 N = 27 N = 33 N = 23
Year, Mean (SD) 2004.5 (5.1) 2001.3 (6.3) 2003.6 (5.2) 2004.5 (4.5) 2006.7 (3.6) 2007.7 (4.5) 2003.8 (3.8) 2006.2 (3.1) 2006.9 (4.0) <0.001
Country, N (%)
US 98 (39.7) 16 (30.8) 12 (33.3) 15 (50.0) 17 (63.0) 3 (16.7) 17 (63.0) 13 (39.4) 5 (21.7) 0.020
Europe 104 (42.1) 22 (42.3) 18 (50.0) 9 (30.0) 8 (28.6) 10 (55.6) 8 (29.6) 14 (42.4) 15 (65.2)
Other 45 (18.2) 14 (26.9) 6 (16.7) 6 (20.0) 3 (10.7) 5 (27.8) 2 (7.4) 6 (18.2) 3 (13.00
Age group, N (%)
Excludes < 65y 147 (59.5) 31 (59.6) 17 (47.2) 13 (43.3) 24 (85.7) 12 (66.7) 20 (74.1) 16 (48.5) 14 (60.9) 0.012
Includes < 65y 100 (40.5) 21 (40.4) 19 (52.8) 17 (56.7) 4 (14.3) 6 (33.3) 7 (25.9) 17 (51.5) 9 (39.1)
Sex, N (%)
Both 208 (84.2) 47 (90.4) 28 (77.8) 28 (93.4) 19 (67.9) 16 (88.9) 22 (81.5) 28 (84.8) 20 (87.0) 0.12
Men only 26 (10.5) 3 (5.8) 8 (22.2) 1 (3.3) 5 (17.9) 2 (11.1) 2 (7.4) 3 (9.1) 2 (8.7)
Women only 13 (5.3) 2 (3.8) 0 (0.0) 1 (3.3) 4 (14.3) 0 (0.0) 3 (11.1) 2 (6.1) 1 (4.3)
Study design, N (%)
Cross-sectional 80 (32.4) 25 (48.1) 7 (19.4) 12 (40.0) 4 (14.3) 7 (38.9) 6 (22.2) 14 (42.4) 5 (21.7) 0.012
Cohort 167 (67.6) 27 (51.9) 29 (80.6) 18 (60.0) 24 (85.7) 11 (61.1) 21 (77.8) 19 (57.6) 18 (78.3)
Sample size, Mean (SD) 3,561 (5,128) 4,345 (6,066) 4,745 (6,859) 4,745 (6,808) 3,322 (3,927) 2,408 (2,385) 3,643 (4,191) 1,074 (769) 3,061 (3,389) 0.05
Cognitive outcome count, N (%)
1 179 (72.5) 34 (65.4) 26 (86.7) 26 (86.7) 20 (71.4) 14 (77.8) 22 (81.5) 21 (63.6) 15 (65.2) 0.77
2 60 (24.3) 15 (28.8) 4 (13.3) 4 (13.3) 7 (25.0) 3 (16.7) 4 (14.8) 10 (30.3) 8 (34.8)
3 5 (2.0) 2 (3.9) 0 (0.0) 0 (0.0) 1 (3.6) 1 (5.6) 0 (0.0) 1 (3.0) 0 (0.0)
4 2 (1.2) 1 (1.9) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.7) 1 (3.0) 0 (0.0)
Cognitive outcome type, N (%) 0.042
AD/dementia/impairment 114 (46.2) 26 (50.0) 20 (55.6) 6 (20.0) 16 (57.1) 5 (27.8) 15 (55.6) 15 (45.5) 11 (47.8)
Cognitive function/decline 126 (51.0) 25 (48.1) 16 (44.4) 24 (80.0) 10 (35.7) 11 (61.1) 12 (44.4) 17 (51.5) 11 (47.8)
Both 7 (2.8) 1 (1.9) 0 (0.0) 0 (0.0) 2 (7.1) 2 (11.1) 0 (0.0) 1 (3.0) 1 (4.4)
Study finding, N(%) 0.004
Against hypothesis 5 (2.0) 1 (1.9) 1 (2.8) 2 (6.7) 1 (3.6) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Null 45 (18.2) 4 (7.7) 11 (30.6) 4 (13.3) 0 (0.0) 5 (27.8) 9 (33.3) 6 (18.2) 6 (26.1)
Positive 152 (61.5) 39 (75.0) 18 (50.0) 17 (56.7) 25 (89.3) 7 (38.9) 11 (40.7) 23 (69.7) 12 (52.2)
Partially positive (outcomes/exposures) 21 (8.5) 6 (11.5) 2 (5.6) 2 (6.7) 0 (0.0) 3 (16.7) 2 (7.4) 1 (3.0) 1 (4.3)
Partially positive (sub-groups) 24 (9.7) 2 (7.7) 4 (11.1) 5 (16.7) 2 (7.1) 3 (16.7) 5 (27.8) 3 (9.1) 4 (17.4)
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(Table 4). Examining the odds ratios and their 95% CI,
taking “null finding/against hypothesis finding” as the ref-
erent category for the outcome, we found that in general,
a positive or partially positive finding was significantly
more likely when the risk factor was “education” particu-
larly when compared to smoking, caffeine and antioxi-
dants/vitamin E (p < 0.05). None of the other study-level
characteristics were associated with the study finding.
Meta-analysis: selected risk factors for incident AD
Using random effects models, we pooled findings of 31
selected data points from 31 studies in which the
outcome was incident AD and for which exposure data was
adequate and comparable across studies (Figure 3A-E).
Among studies used to summarize the association betweenTable 4 Multiple logistic regression: study-level predictors
of study finding*
Odds Ratio (95% CI) P-value
Year 1.06 (0.98;1.14) 0.13
Country
US 1.00
Europe 0.96 (0.45;2.06) 0.92
Other 0.99 (0.35;2.80) 0.99
Age group
Excludes < 65y 1.00
Includes < 65y 0.80 (0.40;1.60) 0.53
Study design
Cross-sectional 1.00
Cohort 0.60 (0.27;1.33) 0.21
Sample size 1.00 (0.99;1.00) 0.25
Cognitive outcome count 1.03 (0.54;1.98) 0.92
Cognitive outcome type
AD/dementia/impairment 1.00
Cognitive function/decline 1.52 (0.72;3.22) 0.27
Both 1.78 (0.16;19.7) 0.64
Risk factor
EDU 1.00
SMOK 0.21 (0.06;0.70) 0.012
ALCO 0.33 (0.08;1.29) 0.11
PA 2.49 (0.26;24.29) 0.43
CAFF 0.18 (0.04;0.84) 0.029
ANTIOX 0.20 (0.06;0.75) 0.016
HCY 0.41 (0.10;1.67) 0.22
N-3 FA 0.25 (0.06;1.05) 0.06
*Positive or partially positive finding coded as “1”, Null or against
hypothesized finding coded as “0” (referent category).
Gender composition of the sample was excluded as a predictor due to lack
of variability.low education and incident AD, the largest study (N =
3,675) found a HR = 1.81 with 95% CI: 1.30–2.53, with
a prevalence of low education being ~32% [43]. In all
four studies, the exposure definition was standardized
as a comparison between <8y of education vs. ≥8y. In
contrast, for all other exposures, definitions differed to
some extent between studies but were assumed to
operationalize the same concept. For instance, high vs.
low physical activity was defined as a frequency of 3
times or more per week by two studies, 2 times of
more per week by one, 4 activities per week by one, ≥2
vs. <2 mile walk/day by another study, and other compar-
able definitions by the remaining four studies combining
frequency and intensity of activity. A full description of




242,250,251]: Notes: Only studies with available data
points on incident AD were selected. Moreover, risk
factors/protective factors needed to be measured in a
comparable manner across studies to allow for estimating
a pooled RR with a 95% CI. For education, only four
studies out of 27 cohort studies had the required inclu-
sion criteria. For smoking status, the common referent
category was non-smoking or never smoking or « never or
former » whereas exposed group consisted of either « ever
smokers » [78,93], or a pooled value for RR to obtain an
approximate « ever smoker » category [86], or current
smokers [82,88,95], or mid-life smoking or heavy smoking
[101,103,104]. For high vs. low physical activity level, two
studies used the cut-point of 3 or more times per week
[133,145], one used 2 times or more per week [142], one
used the criterion of 4 activities per week vs. none [141],
one used > =2 vs. <2 miles walking/day [137], and the
remaining four studies used other definitions related to
both frequency and intensity [148,150,156]. For high vs.
low n-3 fatty acids, one study had fish consumption (yes
vs. no) as the exposure of interest [237], another examined
quintiles of total n-3 PUFA and compared the fifth to the
first quintile in terms of risk for AD [239], a third study
had one main exposure as « weekly consumption of fish
vs. not » [242], a fourth study contrast high vs. no fish
intake, 0-8y follow-up [250], and finally upper quartile
vs. lowest quartile for total n-3 PUFA in erythrocyte
membranes [251]. For high vs. low Hcy, two studies
used a cut-point of 14.6 μmol/L [206,215], one study
used a cut-point of 15 μmol/L [217], one study used upper
vs. lowest quartile [209] and one study used upper tertile
vs. lowest tertile [233].
Tests of heterogeneity, including the Q-tests, deter-
mined whether to use fixed-effects or random-effects
models to pool the RR. Findings indicated that, with the
exception of education and smoking as main exposures,
RR
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Figure 3 Meta-analysis of selected risk and protective factors for incident AD (n = 31). (A) Education. (B) Smoking status. (C) Physical
activity. (D) Homocysteine. (E) n3 fatty acids.
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homogenous. In sum, the pooled RRs were: 1.99 (1.30,
3.04) for low vs. higher educational attainment (n = 4 data
points; Q = 11.33, p = 0.010); 1.37(1.23-1.52) for smoking
status (current or ever vs. never smokers (n = 9 data
points, Q = 36.2, p < 0.001); 0.58(0.49, 0.70) for physical
activity (n = 8 data points, Q = 3.2, p = 0.867), 0.67
(0.47,0.96) for high intake of n-3 fatty acids (n = 5, Q = 7.4,
p = 0.116), and RR = 1.93(1.50, 2.49) for high levels of
plasma Hcy (n = 5 data points; Q = 2.64, p = 0.620).
Taking the largest study for each as a means to obtain
an estimate of exposure prevalence, the following was
found: low education (32%) [43], mid-life smoking (59.8%)
[93], lower physical activity (62%) [150], lower n-3 fatty
acids (49.4%) [242], elevated Hcy (30%) [206]. From theseexposure prevalence estimates (Prevexp), we computed the
PAR% and its 95% CI to assess the proportion of AD that
is attributable to each exposure in a typical adult popula-
tion and thus the % that can be averted if that exposure
was eliminated from that population. Our findings indi-
cated that the PAR% for low education was 24.0% with a
95% CI: 8.4-39.6; for mid-life smoking it was 31.0% with a
95% CI: 17.9-44.3; for physical activity (lower vs. higher) it
was 31.9% with 95% CI: 22.7-41.2; for high vs. low Hcy, it
was 21.7% with a 95% CI: 12.8-30.6; for lower vs. higher
fish consumption (<weekly vs. ≥weekly), it was 21.9% with
95% CI:4.7-39.1.
Publication bias for the meta-analysis data points
(n = 31) was assessed using primarily the funnel plot
which plotted point estimates of RR for all exposures
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This plot indicated that estimates obtained from those 31
studies lay within the pseudo 95% confidence limits, an
indication of non-appreciable publication bias. This finding
was reinforced by a non-significant Begg-adjusted rank cor-
relation test (Z = 0.25; P = 0.80), and by Egger’s regression
asymmetry test (bias (SE): -0.43 (0.98); p = 0.66) (Additional
file 1: Figure S1).
Discussion
As stated earlier, this is the first study to systematically
review those selected modifiable risk and protective
factors for cognitive health outcomes in cross-sectional
and cohort studies while comparing the consistency of as-
sociation between those factors and across study-level
characteristics. It is also among few recent studies to com-
pare the strength of association across those factors in re-
lation to incident AD using a similar approach [19,20].
However, our study has a few limitations. First, the litera-
ture search was limited to published articles in English
available in the Medline database. Second, comparing all
included studies in a quantitative meta-analytic manner
was not possible due to the diversity of the cognitive out-
come measurements between original studies included. In
fact, cognitive measures included scores from batteries of
different cognitive tests, single global cognitive test scores
such as the MMSE total score, as well as the use of a fac-
tor analytic approach to combine test scores into various
domains of interest (e.g. memory, spatial, psychomotor,
executive function, attention). Thus, meta-analysis was
only possible for measures of cognitive impairment (i.e.
MCI, all-cause dementia, AD, VaD) from which we
selected incident AD as the most comparable outcome
across studies. However, in order to measure consistency
across the selected studies and compare risk factors in
terms of consistency, we conducted another type of ana-
lysis in which a qualitative outcome of “study finding” was
modeled against study-level characteristics. The qualifica-
tion of a finding as null or positive was based on the main
conclusion of each study that was included. This type of
analysis does not necessarily discriminate between null
findings due to low power, poor quality study vs. actual
null finding. However, our logistic regression analysis
indicated that overall, sample size was not a determin-
ing factor for the study finding outcome. Combining
findings from meta-analysis and the consistency ana-
lyses, we compared evidence level for each risk and
protective factor of cognitive health. Other limitations
include the lack of comparability in measurements of
risk or protective factors in studies with incident AD,
which resulted in the exclusion of a few data points in
our meta-analysis. However, the datapoints that were
included in the meta-analysis were relatively comparable
as described in the footnotes of Figure 3A-E. Finally, ourstudy was limited by the inability to create a common
quality measure for all studies given the diversity of the
exposure variables and the relative importance of having a
large sample size given the type of exposure (e.g., a larger
sample size is needed for a questionnaire-based exposure
vs. a blood level based exposure).
Our review shows that over the past several decades
many risk or protective factors have been studied in re-
lation to cognitive impairment, dementia (including AD)
and cognitive decline. Overall, these studies indicate that
modifiable factors including individuals’ socio-economic,
behavioral characteristics and dietary intake seem to
affect people’s cognitive ability and change over time, as
well as the incidence of cognitive impairment, all-cause
dementia and AD. It is worth noting, however, that some
of the diagnostic criteria for dementia, AD and MCI
have changed over time, particularly between the 1990s
and the more recent years, as shown in Table 1.
In total, 247 studies were retrieved for systematic review.
When conducting consistency analysis for each risk factor/
design dyad, we found the % of studies with positive
finding, given hypothesis, for most outcomes and study
participants to range from ~38.9% for caffeine (27.3 for
cohort studies (n = 11), 57.1% for cross-sectional studies
(n = 7)) to ~89% for physical activity(87.5% for cohort
studies(n = 24); 100% for cross-sectional studies(n = 4)).
Consistency analysis confirmed that education-related
studies had a significantly higher propensity for a positive
or partially positive finding compared to caffeine, smoking
and antioxidant-related studies. Meta-analysis of 31 stud-
ies with incident AD and selected risk/protective factors
yielded pooled RR and 95% CI as follows: RR = 1.99(1.30,
3.04) for low(risk factor) vs. higher education (n = 4 studies;
Q = 11.33, p = 0.010); RR = 1.37(1.23, 1.52) for smoking
status (current or ever(risk factor) vs. never smokers (n = 9
studies, Q = 36.2, p < 0.001); RR = 0.58(0.49, 0.70) for higher
physical activity(protective factor) vs. lower (n = 8 studies,
Q = 3.2, p = 0.867), RR = 0.67(0.47,0.96) for higher intake
of n-3 fatty acids(protective factor) vs. lower (n = 5, Q = 7.4,
p = 0.116), and RR = 1.93(1.50, 2.49) for high levels of
plasma Hcy(risk factor) vs. lower (n = 6 data points;
Q = 2.64, p = 0.620). Given the observed prevalence of
exposure from the largest study per risk factor included
in each meta-analysis, the population attributable risk
percent (PAR%) with its 95% CI was estimated as fol-
lows: for low education: 24.0% with a 95% CI: 8.4-39.6;
for mid-life smoking it was 31.0% with a 95% CI: 17.9-
44.3; for physical activity (lower vs. higher) it was
31.9% with 95% CI: 22.7-41.2; for high vs. low Hcy, it
was 21.7% with a 95% CI: 12.8-30.6; for lower vs. higher
fish consumption (<weekly vs. ≥weekly), it was 21.9%
with 95% CI:4.7-39.1. There was no significant publication
bias, taking all selected risk factors for incident AD
together.
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conducted to examine the effects of socio-economic fac-
tors, mainly educational attainment, and were later used
to assess the validity of alternative hypotheses regarding
the presence of behavioral or health-related mediating
factors. To this end, several behavioral and nutritional
risk factors were studied in relation to various cognitive
outcomes. For instance, it was hypothesized that low
SES was associated with higher prevalence of smoking
which in turn may affect cognitive performance and change
over time. While few studies found weak or no association
between smoking and cognitive decline, many others found
a positive association whereby smoking increased the risk of
decline. Alcohol was found in general to have a U-shaped
association with the risk of decline, while caffeine was
shown to increase perceptual speed and vigilance as well
as memory and other more complex functions in at least
two cohort studies and one cross-sectional study. Physical
activity was shown to protect against cognitive decline as
corroborated by a number of prospective cohort studies.
Among nutritional factors, dietary and supplemental
antioxidants were shown in some studies to reduce the
risk of cognitive decline while in others they showed
no appreciable effect. Other micronutrients including
B-Vitamins and folate were shown to be protective
against cognitive decline, through their dampening effect
on plasma Hcy which was shown to consistently increase
the risk of dementia, particularly of the AD type. In
addition, studies show that n-3 fatty acids with their anti-
inflammatory and cardio-protective properties can help
reduce the risk of cognitive decline and impairment in
some studies but not in others. Among nutritional factors,
caffeine seems to be the factor hypothesized to have a pro-
tective effect with the smallest number of current studies.
Conclusions
In conclusion, the consistency of findings between studies
varied for each selected risk or protective modifiable fac-
tors (highest consistency observed for physical activity).
Secondly, a moderate to strong association was observed
between some selected factors and incident AD (strongest
for low education and elevated Hcy). Combining both
criteria (strength of association in the case of incident AD
and consistency overall), the strongest evidence thus far is
an increased risk with elevated plasma Hcy levels or lower
educational attainment and a lowered risk with increased
physical activity. Nevertheless, more studies are needed to
verify the consistency, particularly regarding caffeine. A
comprehensive meta-analysis requires additional research
for certain risk factors of incident AD or dementia. For
incident AD, selected risk factors may potentially account
on average for 21.7%-31.9% of AD cases for each risk factor
considered (with 95% CI: 8.4%-44.3%) (highest for mid-
life smoking and physical activity), given the estimatedprevalence of those factors from the largest available study.
Thus, on average, one in five to one in three cases of
AD can potentially be averted if those risk factors were
eliminated from populations with comparable exposure
prevalence.
Additional file
Additional file 1: Figure S1. Begg’s funnel plot with pseudo 95%
confidence limits.
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